ONCY Oncolytics Biotech Inc.

2.23
-0.07  -3%
Previous Close 2.3
Open 2.27
52 Week Low 1.87
52 Week High 4.83
Market Cap $122,560,069
Shares 41,656,998
Float 54,282,604
Enterprise Value $57,839,240
Volume 184,917
Av. Daily Volume 186,219
Stock charts supplied by TradingView

Upcoming Catalysts

Drug Stage Catalyst Date
Pelareorep and OPDIVO (nivolumab) - (WINSHIP 4398-18)
Multiple myeloma
Phase 1
Phase 1
Premium membership is required to view catalyst dates, analyst ratings, earnings dates and cash burn data. Click here to unlock and sign up to a 14-day FREE TRIAL.
Pelareorep and retifanlimab (INCMGA00012) - IRENE
Triple-negative breast cancer.
Phase 2
Phase 2
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.
Pelareorep and TECENTRIQ (atezolizumab) - AWARE-1
Breast cancer
Phase 1
Phase 1
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Quisque sapien.

Drug Pipeline

Drug Stage Notes
Pelareorep, (Taxol) paclitaxel and BAVENCIO (avelumab) - BRACELET-1
HR+ / HER2- breast cancer
Phase 2
Phase 2
Phase 2 initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy in Chinese patients, noted October 14, 2021.
Pelareorep and TECENTRIQ (atezolizumab) - GOBLET
Colorectal and advanced anal cancers
Phase 1/2
Phase 1/2
Phase 1/2 initiation of dosing due 2H 2021.
Pelareorep and KYPROLIS (carfilzomib) / Dexamethasone
Multiple myeloma
Phase 1
Phase 1
Phase 1 interim data noted ORR 50% - May 29, 2020 at ASCO.
Pelareorep with KEYTRUDA (pembrolizumab) - (NU 18I01)
Pancreatic cancer
Phase 2
Phase 2
Phase 2 final data presented at ASCO June 4, 2021. Data in abstract noted response rate 1/12 (8.3%); stable disease 42%.

Latest News

  1. SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.

    Conference Call & Webcast

    Date: Friday, November 5, 2021
    Time: 8:00 a.m. Eastern Daylight Time
    Dial In – North American Toll-Free: (888) 664-6383
    Dial In – International: (416) 764-8650
    Conference ID (if needed): 7285-9440
    Webcast: please click here

    A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one…

    SAN DIEGO and CALGARY, AB, Oct. 19, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that it will host a conference call and webcast on Friday, November 5, 2021, at 8:00 a.m. ET to discuss a corporate update and financial results for the third quarter of 2021.

    Conference Call & Webcast

    Date: Friday, November 5, 2021

    Time: 8:00 a.m. Eastern Daylight Time

    Dial In – North American Toll-Free: (888) 664-6383

    Dial In – International: (416) 764-8650

    Conference ID (if needed): 7285-9440

    Webcast: please click here

    A webcast of the call will also be available on the Investor Relations page of Oncolytics' website, available by clicking here, and will be archived for three months. A dial in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using replay code: 859-440#.

    About Oncolytics Biotech Inc.

    Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes, and benefits of its current or pending clinical trials involving pelareorep; our goals, objectives and strategies; and other statements related to anticipated developments in Oncolytics' business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

     

    Company Contact

    Jon Patton

    Director of IR & Communication

    +1-858-886-7813

    jpatton@oncolytics.ca

    Investor Relations for Oncolytics

    Timothy McCarthy

    LifeSci Advisors

    +1-917-679-9282

    tim@lifesciadvisors.com

     

     

    Cision View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-host-conference-call-to-discuss-third-quarter-financial-results-and-operational-highlights-301403482.html

    SOURCE Oncolytics Biotech Inc.

    View Full Article Hide Full Article
  2. Trial is designed to advance pelareorep's clinical development in China, the world's second-largest pharmaceutical market

    SAN DIEGO and CALGARY, AB, Oct. 14, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that its partner Adlai Nortye has initiated dosing in a bridging clinical trial evaluating the safety, tolerability, and preliminary efficacy of pelareorep-paclitaxel combination therapy in Chinese patients with advanced or metastatic breast cancer.

    Results from the bridging trial are expected to allow Adlai Nortye to include data from Oncolytics' North American metastatic breast cancer trials in a future submission to Chinese regulators. The first of Oncolytics' randomized phase 2 trials, IND-213, showed that treatment with pelareorep and paclitaxel led to a statistically significant increase in overall survival compared to treatment with paclitaxel alone. Oncolytics' second randomized phase 2 trial, BRACELET-1, is ongoing and evaluates pelareorep-paclitaxel combination therapy both with and without a checkpoint inhibitor.

    "Adlai's bridging trial is an important step forward for pelareorep's clinical development path in China, which has a rapidly growing pharmaceutical market that is currently the second-largest in the world," said Andrew de Guttadauro, President of Oncolytics Biotech U.S. and Global Head of Business Development. "We are very pleased that dosing in the trial has commenced and congratulate our partner on this notable achievement. Looking ahead, we are eager to continue our partnership with Adlai as we work to advance pelareorep towards registration in major global markets."

    About Breast Cancer

    Breast cancer is the most common cancer in women worldwide, with over two million new cases diagnosed in 2018, representing about 25 percent of all cancers in women. It is the second leading cause of death from cancer in women in America, with an estimated 42,000 deaths in the U.S. in 2020.1 In China, breast cancer is now estimated to be the largest subtype of cancer among women, with over 416,000 cases and over 117,000 deaths in 2020.2

    Breast cancer starts when cells in the breast begin to grow out of control. These cells usually form a tumor that can often be seen on an x-ray or felt as a lump. The malignant tumor (cancer) gets worse when the cells grow into (invade) surrounding tissues or spread (metastasize) to distant areas of the body.

    About Adlai Nortye

    Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, the Company has built a global pipeline through collaborations and internal discovery with more than 10 drug candidates in development. Currently, three of them are being investigated in clinical trials, including the FDA Fast-Track designated Buparlisib (AN2025) in a global phase III clinical trial; the FDA Fast-Track designated intravenously administered oncolytic virus Pelareorep (AN1004) to have completed a phase II clinical trial; and an oral EP4 antagonist (AN0025) is in early-stage clinical development in multiple tumor types in combination with other treatment options including chemo-radiation and anti–PD–1/anti–PD–L1 therapies.

    The Company has assembled a world-class management team, built its unique immuno-oncology platforms and partnered with multiple top pharmaceutical companies to promote innovation. Adlai Nortye is committed to becoming an innovative biopharmaceutical company with global vision and strives to benefit patients worldwide. The ultimate goal of the Company is to transform cancer into manageable conditions. For more information, please visit: www.adlainortye.com.

    About Oncolytics Biotech Inc.

    Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

    References:

    1.  "Breast Cancer Statistics and Resources." Breast Cancer Research Foundation. https://www.bcrf.org/breast-cancer-statistics-and-resources

    2.  Cao, Wei, et al; Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020, Chinese Medical Journal: April 5, 2021 - Volume 134 - Issue 7 - p 783-791. doi:10.1097/CM9.0000000000001474; https://journals.lww.com/cmj/Fulltext/2021/04050/Changing_profiles_of_cancer_burden_worldwide_and.5.aspx

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; the anticipated timing of completion of enrollment in Oncolytics' BRACELET-1 study; our goals, objectives and strategies; and other statements related to anticipated developments in Oncolytics' business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

    Company Contact

    Jon Patton

    Director of IR & Communication

    +1-858-886-7813

    jpatton@oncolytics.ca

    Investor Relations for Oncolytics

    Timothy McCarthy

    LifeSci Advisors

    +1-917-679-9282

    tim@lifesciadvisors.com 

     

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotechpartner-adlai-nortye-doses-first-patient-in-chinese-bridging-trial-evaluating-pelareorep-paclitaxel-combination-treatment-in-breast-cancer-301400289.html

    SOURCE Oncolytics Biotech® Inc.

    View Full Article Hide Full Article
  3. SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris, France from September 14 – 17, 2021.

    Oncolytics Logo

    Preclinical studies presented in the poster evaluated various treatment combinations of pelareorep, ionizing radiation (radiotherapy), and anti-PD-1 therapy in mice with two bilateral tumors, each located subcutaneously (under the skin) on a different side of the body. Radiotherapy and/or pelareorep…

    SAN DIEGO and CALGARY, AB, Sept. 20, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced preclinical data demonstrating the synergistic immunotherapeutic effects of pelareorep combined with radiotherapy in a murine cancer model. The data were featured in a poster presentation at The International Conference on Immunotherapy Radiotherapy Combinations, which took place in Paris, France from September 14 – 17, 2021.

    Oncolytics Logo

    Preclinical studies presented in the poster evaluated various treatment combinations of pelareorep, ionizing radiation (radiotherapy), and anti-PD-1 therapy in mice with two bilateral tumors, each located subcutaneously (under the skin) on a different side of the body. Radiotherapy and/or pelareorep treatment was delivered locally to one tumor (denoted the primary tumor), while the second tumor (denoted the abscopal tumor) was not directly exposed to either therapy. Anti-PD-1 therapy was delivered systemically.

    Results showed that in primary tumors, pelareorep monotherapy led to a numerical increase in the number of infiltrating anti-cancer CD8+ T cells, which reached statistical significance when combined with radiotherapy (a 15-fold increase compared to control). In abscopal tumors, both pelareorep monotherapy and pelareorep-radiation combination therapy led to a statistically significant increase in infiltrating anti-cancer CD8+ T cells. This effect was not seen with single-agent radiotherapy in either the primary or the abscopal tumors.

    Local delivery of radiotherapy alone and the pelareorep-radiotherapy combination into primary tumors significantly improved survival compared to untreated controls. Compared to single-agent radiotherapy, the pelareorep-radiotherapy combination led to a numerical increase in survival, which reached statistical significance when anti-PD-1 therapy was added to the treatment regimen.

    "The observed increases in survival and in the number of anti-cancer immune cells within both primary and abscopal tumors following treatment is indicative of the synergistic immunotherapeutic effects of the pelareorep-radiotherapy combination," said Thomas Heineman, M.D., Ph.D., Global Head of Clinical Development and Operations at Oncolytics. "This is a compelling finding that has the potential to be broadly applicable across multiple cancer indications and warrants further study. Together with prior clinical and preclinical data, these results also highlight pelareorep's potential as an enabling technology to enhance the efficacy of a wide range of therapies."

    A copy of the poster titled, "Combination treatment with radiotherapy and oncolytic reovirus generates CD8+ T cell infiltration in primary and abscopal tumours in an organoid model of basal-like breast cancer," can be found on the Posters & Publications page of Oncolytics' website (LINK).

    About Oncolytics Biotech Inc.

    Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved immuno-oncology agents. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies, as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the mode of action and potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our goals, objectives and strategies; and other statements related to anticipated developments in Oncolytics' business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

    Company Contact

    Jon Patton

    Director of IR & Communication

    +1-858-886-7813

    jpatton@oncolytics.ca

    Investor Relations for Oncolytics

    Timothy McCarthy

    LifeSci Advisors

    +1-917-679-9282

    tim@lifesciadvisors.com 

    Logo - https://mma.prnewswire.com/media/1064079/Oncolytics_Logo.jpg

     

    Cision View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-preclinical-data-demonstrating-the-synergistic-immunotherapeutic-effects-of-pelareorep-combined-with-radiotherapy-301379841.html

    SOURCE Oncolytics Biotech® Inc.

    View Full Article Hide Full Article
  4. - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer

    - Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021

    - Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types

    - Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023

    - Management hosting conference call and webcast today at 8:00 a.m. ET

    SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX…

    - Clinical AWARE-1 trial achieves primary endpoint and confirms that pelareorep is an immunotherapeutic agent which synergizes with checkpoint inhibitors: Validation of clinical development strategy in breast cancer

    - Phase 2 BRACELET-1 (breast cancer) trial remains on track for full enrollment in Q4 2021

    - Highly encouraging clinical proof-of-concept data in metastatic pancreatic cancer demonstrate pelareorep's broad applicability to a number of different tumor types

    - Strong financial foundation with approximately $50.8 million in cash on hand and cash runway into 2023

    - Management hosting conference call and webcast today at 8:00 a.m. ET

    SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced its financial results and development highlights for the quarter ended June 30, 2021. All dollar amounts are expressed in Canadian currency unless otherwise noted.

    Oncolytics_Logo

    "Our second quarter accomplishments have advanced our lead clinical breast cancer program down a clear path towards a registrational study and substantially de-risked our broader clinical pipeline," said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics Biotech Inc. "Clinical AWARE-1 data show that pelareorep is an immunotherapeutic agent that synergistically combines with checkpoint inhibitors. These findings support the statistically significant overall survival benefit observed in our prior phase 2 breast cancer trial, achieving a key regulatory objective. They also suggest that pelareorep's efficacy can be further enhanced by combining it with checkpoint inhibition. We are currently working to confirm this hypothesis in the BRACELET-1 breast cancer trial, which will support pelareorep's advancement to a registrational study."

    Dr. Coffey continued, "Beyond our lead program, we also presented clinical proof-of-concept data in pancreatic cancer that further demonstrate pelareorep's immunologic mechanism of action and potential to address unmet needs across multiple indications. Together with AWARE-1 data, these results support our ongoing trials evaluating pelareorep-checkpoint inhibitor combinations and highlight pelareorep's potential as an enabling technology for multiple classes of immunotherapeutic agents. Looking forward, our strong financial foundation leaves us well-positioned to build on this momentum and advance pelareorep's clinical development. As we work towards this goal, we will remain primarily focused on breast cancer and our stated clinical milestones while pursuing a partnership strategy to further broaden pelareorep's potential impact." 

    Second Quarter and Subsequent Highlights

    Breast Cancer Program

    Achieved primary endpoint in AWARE-1 study

    Data from the twenty HR+/HER2- early-stage breast cancer patients included in AWARE-1's first two cohorts were presented in an electronic poster at the American Association for Cancer Research (AACR) Annual Meeting 2021 (link to PR; link to poster). Results from these patients, who were treated with pelareorep and letrozole without (cohort 1) or with (cohort 2) the PD-L1 inhibitor atezolizumab (Tecentriq®), showed that that pelareorep and letrozole treatment upregulated tumor PD-L1 expression, induced the generation and expansion of T cell clones, promoted tumor infiltration of CD8+ T cells, and increased CelTIL score, a measure of tumor cellularity and inflammation that is significantly correlated with event-free and overall survival. These desirable effects were further enhanced in patients receiving atezolizumab, demonstrating that pelareorep and atezolizumab synergistically combine to generate an anti-cancer immune response in the tumor and peripheral blood. Notably, cohort 2 met the pre-specified success criteria for the study's primary endpoint, with six of ten patients achieving at least a 30% increase in CelTIL score following treatment. Together, these data support the results of a prior successful phase 2 trial (IND-213) that showed a statistically significant near doubling of overall survival with pelareorep treatment. This supports the clinical rationale behind the phase 2 BRACELET-1 trial: Evaluating the safety and efficacy of pelareorep and chemotherapy alone, and in combination with a PD-L1 inhibitor, in HR+/HER2- breast cancer patients.

    Gastrointestinal Cancers Program

    Phase 2 data demonstrating clinical proof-of-concept for pelareorep-checkpoint inhibitor combination therapy in pancreatic cancer

    Data from a phase 2 trial evaluating pelareorep in combination with the PD-1 inhibitor pembrolizumab (KEYTRUDA®) in pancreatic adenocarcinoma patients who progressed after first-line treatment were featured in an electronic poster presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting (link to PR; link to poster). Findings from the trial indicate that pelareorep and pembrolizumab synergize and show anti-cancer activity in these difficult-to-treat patients, with a 42% disease control rate achieved and durations of control ranging from approximately 2.5 months to approximately 7 months despite the absence of chemotherapy in the treatment regimen. Biomarker data showed that patients achieving disease control had increased activation of anti-cancer CD8+ T cells in the peripheral blood, and reduced levels of pro-tumor Treg cells in the peripheral blood and tumor compared to those with progressive disease. These results, which are consistent with what has been seen in clinical trials in other indications, such as breast cancer, highlight the broad applicability of pelareorep's immunotherapeutic mechanism of action. They also bode well for a successful outcome in the phase 1/2 GOBLET trial, which includes a cohort evaluating pelareorep and the PD-L1 inhibitor atezolizumab in combination with chemotherapy as a first-line treatment in metastatic pancreatic cancer patients (link to PR).

    Additional Immunotherapeutic Combinations and Opportunities

    Preclinical data highlighting pelareorep's ability to synergize with multiple classes of anti-cancer agents

    Data presented in two electronic poster presentations at the AACR Annual Meeting 2021 showed that pelareorep enhanced the anti-tumor efficacy of the poly(ADP)-ribose polymerase 1 (PARP-1) inhibitor talazoparib and the cyclin-dependent kinase (CDK) 4/6 inhibitor palbociclib, which are both FDA approved for the treatment of breast cancer. The observed synergistic effects were notably mediated through immunologic mechanisms rather than through the molecular pathways typically associated with PARP-1 and CDK4/6 inhibition  (link to PR; link to CDK4/6 poster; link to PARP-1 poster). Together, these results suggest that pelareorep may enhance the therapeutic potential of PARP-1 and CDK4/6 inhibitors by expanding the mechanisms by which they exert anti-tumor effects.

    Changes to the Board of Directors

    William G. Rice, Ph.D. has stepped down from Oncolytics Biotech's Board of Directors to avoid any potential conflicts that might arise from the development of pelareorep with molecules being developed by Aptose Biosciences Inc., the company for which Dr. Rice serves as Chairman of the Board, President & Chief Executive Officer. "I'm a staunch supporter of Oncolytics and wish to express my sincere gratitude for the time serving the Board and working with a wonderful group of directors and officers," stated Dr. Rice. Oncolytics would like to thank Dr. Rice for his guidance during his tenure as a member of the Board.

    Financial Highlights

    • As of June 30, 2021, the Company reported $50.8 million in cash and cash equivalents. The Company raised $8.1 million during the second quarter through issuing of common stock through its ATM facility.
    • Operating expense for the second quarter of 2021 was $3.5 million, compared to $3.0 million in the second quarter of 2020.
    • R&D expense for the second quarter of 2021 was $3.2 million, compared to $2.5 million in the second quarter of 2020.
    • Net cash used in operating activities for the second quarter of 2021 was $6.8 million, compared to $6.3 million for the second quarter of 2020.
    • The net loss for the second quarter of 2021 was $7.2 million, compared to a net loss of $6.8 million in the second quarter of 2020. The basic and diluted loss per share was $0.13 in the second quarter of 2021, compared to a basic and diluted loss per share of $0.17 in the second quarter of 2020.

    Anticipated Milestones and Catalysts

    • Dosing of the first patient in phase 1/2 GOBLET study in gastrointestinal cancer: H2 2021
    • Final biomarker data for AWARE-1 breast cancer study in the intended target population for a registrational study: H2 2021
    • Completion of enrollment in phase 2 BRACELET-1 metastatic breast cancer study: Q4 2021
    • Interim safety update from phase 2 IRENE study in triple-negative breast cancer: Q4 2021*
    • Interim safety data from phase 1 WINSHIP 4398-18 multiple myeloma study: Q4 2021*

    *Guidance provided by clinical investigators

    Oncolytics expects to provide updates on the timing of the following milestones:

    • Interim safety update from BRACELET-1 metastatic breast cancer study
    • Phase 2 BRACELET-1 metastatic breast cancer study: final data

    Webcast and Conference Call

    Management will host a conference call for analysts and institutional investors at 8:00 a.m. ET today, August 6, 2021. To access the call, please dial (888) 664-6383 (North America) or (416) 764-8650 (International) and, if needed, provide confirmation number 5114-8191. A live webcast of the call will also be available by clicking here or on the Investor Relations page of Oncolytics' website (LINK) and will be archived for three months. A dial-in replay will be available for one week and can be accessed by dialing (888) 390-0541 (North America) or (416) 764-8677 (International) and using reference code: 148-191#.

     

     



    ONCOLYTICS BIOTECH INC.

    INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION

    (unaudited)

    (in Canadian dollars, except share amounts)





    As at

    June 30,

    2021

    $

    December 31,

    2020

    $

    Assets





    Current assets





    Cash and cash equivalents

    50,799,432



    31,219,574



    Other receivables

    135,857



    89,661



    Prepaid expenses

    4,503,776



    2,427,200



    Total current assets

    55,439,065



    33,736,435



    Non-current assets





    Property and equipment

    146,216



    236,664



    Right-of-use assets

    724,164



    372,468



    Total non-current assets

    870,380



    609,132









    Total assets

    56,309,445



    34,345,567



    Liabilities And Shareholders' Equity





    Current Liabilities





    Accounts payable and accrued liabilities

    2,193,979



    1,805,015



    Other liabilities



    123,985



    Lease liabilities

    234,139



    248,885



    Warrant derivative

    153,968



    531,228



    Total current liabilities

    2,582,086



    2,709,113



    Non-current liabilities





    Contract liability

    6,730,287



    6,730,287



    Lease liabilities

    510,369



    153,174



    Total non-current liabilities

    7,240,656



    6,883,461









    Total liabilities

    9,822,742



    9,592,574



    Commitments and contingencies





    Shareholders' equity





    Share capital

     Authorized: unlimited

     Issued: June 30, 2021 – 54,959,672

      December 31, 2020 – 46,166,980

    391,124,995



    356,824,172



    Warrants

    3,617,570



    3,617,570



    Contributed surplus

    32,224,806



    31,022,356



    Accumulated other comprehensive income

    311,543



    400,225



    Accumulated deficit

    (380,792,211)



    (367,111,330)



    Total shareholders' equity

    46,486,703



    24,752,993



    Total liabilities and shareholder's equity

    56,309,445



    34,345,567



     

     



    ONCOLYTICS BIOTECH INC.

    INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS

    (unaudited)

    (in Canadian dollars, except share amounts)





    Three Months

    Ended June

    30, 2021

    $

    Three Months

    Ended June

    30, 2020

    $

    Six Months

    Ended June

    30, 2021

    $

    Six Months

    Ended June

    30, 2020

    $











    Expenses









       Research and development

    3,203,181



    2,499,128



    5,962,195



    5,028,774



       Operating

    3,520,986



    3,048,572



    6,662,876



    6,041,960



    Loss before the following

    (6,724,167)



    (5,547,700)



    (12,625,071)



    (11,070,734)



       Change in fair value of warrant derivative

    80,159



    (507,150)



    (84,621)



    3,644,832



    Foreign exchange (loss) gain

    (631,352)



    (805,098)



    (1,021,906)



    899,707



       Interest income, net

    29,224



    32,533



    50,717



    98,442



    Loss before income taxes

    (7,246,136)



    (6,827,415)



    (13,680,881)



    (6,427,753)



       Income tax expense









    Net loss

    (7,246,136)



    (6,827,415)



    (13,680,881)



    (6,427,753)



    Other comprehensive (loss) income items

    that may be reclassified to net loss









      Translation adjustment

    (48,370)



    (146,443)



    (88,682)



    148,769



    Net comprehensive loss

    (7,294,506)



    (6,973,858)



    (13,769,563)



    (6,278,984)



    Basic and diluted loss per common share

    (0.13)



    (0.17)



    (0.26)



    (0.17)



    Weighted average number of shares (basic

    and diluted)

    54,325,212



    39,603,671



    52,008,768



    37,734,689



     

     

    ONCOLYTICS BIOTECH INC.

    INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

    (unaudited)

    (in Canadian dollars)





    Share Capital

    $

    Warrants

    $

    Contributed Surplus

    $

    Accumulated

    Other Comprehensive Income

    $

    Accumulated Deficit

    $

    Total

    $

    As at December 31, 2019

    311,077,859



    3,617,570



    29,338,849



    464,101



    (344,606,273)



    (107,894)



    Net loss and other comprehensive loss







    148,769



    (6,427,753)



    (6,278,984)



    Issued pursuant to stock option plan

    162,812





    (60,024)







    102,788



    Issued pursuant to incentive share award plan

    289,686





    (289,686)









    Issued pursuant to "At the Market" Agreement

    24,359,150











    24,359,150



    Issued pursuant to warrant derivative exercised

    6,332,778











    6,332,778



    Share-based compensation





    653,445







    653,445



    Share issue costs

    (1,072,119)











    (1,072,119)



    As at June 30, 2020

    341,150,166



    3,617,570



    29,642,584



    612,870



    (351,034,026)



    23,989,164

















    As at December 31, 2020

    356,824,172



    3,617,570



    31,022,356



    400,225



    (367,111,330)



    24,752,993



    Net loss and other comprehensive income







    (88,682)



    (13,680,881)



    (13,769,563)



    Issued pursuant to stock option plan

    313,867





    (117,751)







    196,116



    Issued pursuant to incentive share award plan

    370,117





    (370,117)









    Issued pursuant to "At the Market" Agreement

    34,168,071











    34,168,071



    Issued pursuant to warrant derivative exercised

    686,616











    686,616



    Share-based compensation





    1,690,318







    1,690,318



    Share issue costs

    (1,237,848)











    (1,237,848)



    As at June 30, 2021

    391,124,995



    3,617,570



    32,224,806



    311,543



    (380,792,211)



    46,486,703



     

     

    ONCOLYTICS BIOTECH INC.

    INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS

    (unaudited)

    (in Canadian dollars)





    Three Months

    Ended June

    30, 2021

    $

    Three Months

    Ended June

    30, 2020

    $

    Six Months

    Ended June

    30, 2021

    $

    Six Months

    Ended June

    30, 2020

    $











    Operating Activities









    Net loss for the period

    (7,246,136)



    (6,827,415)



    (13,680,881)



    (6,427,753)



    Depreciation - property and equipment

    75,340



    22,584



    95,890



    45,629



    Depreciation - right-of-use-assets

    88,493



    92,133



    174,677



    183,156



    Share-based compensation

    1,032,242



    260,640



    1,690,318



    653,445



    Interest expense on lease liabilities

    24,450



    14,885



    38,259



    33,094



    Unrealized foreign exchange loss (gain)

    713,763



    699,079



    1,233,131



    (728,677)



    Change in fair value of warrant derivative

    (80,159)



    507,150



    84,621



    (3,644,832)



    Net change in non-cash working capital

    (1,404,875)



    (1,027,687)



    (2,001,354)



    (327,950)



    Cash used in operating activities

    (6,796,882)



    (6,258,631)



    (12,365,339)



    (10,213,888)



    Investing Activities









    Acquisition of property and equipment

    (6,598)



    (3,034)



    (6,598)



    (13,749)



    Cash used in investing activities

    (6,598)



    (3,034)



    (6,598)



    (13,749)



    Financing Activities









    Proceeds from exercise of stock options

    6,766



    17,638



    196,116



    102,788



    Proceeds from exercise of warrant derivative



    263,318



    230,946



    1,696,460



    Proceeds from "At the Market" equity distribution agreement

    8,072,561



    6,449,218



    32,930,223



    23,287,031



    Payment of lease liabilities

    (98,555)



    (119,634)



    (210,228)



    (233,108)



    Cash provided by financing activities

    7,980,772



    6,610,540



    33,147,057



    24,853,171



    Increase in cash

    1,177,292



    348,875



    20,775,120



    14,625,534



    Cash and cash equivalents, beginning of period

    50,362,162



    30,567,480



    31,219,574



    14,148,021



    Impact of foreign exchange on cash and cash equivalents

    (740,022)



    (1,005,004)



    (1,195,262)



    1,137,796



    Cash and cash equivalents, end of period

    50,799,432



    29,911,351



    50,799,432



    29,911,351



     

    About AWARE-1

    AWARE-1 is an open label window-of-opportunity study in early-stage breast cancer enrolling 38 patients into five cohorts:

    • Cohort 1 (n=10), HR+ / HER2- (pelareorep + letrozole)
    • Cohort 2 (n=10), HR+ / HER2- (pelareorep + letrozole + atezolizumab)
    • Cohort 3 (n=6), TNBC (pelareorep + atezolizumab)
    • Cohort 4 (n=6), HR+ / HER2+ (pelareorep + trastuzumab + atezolizumab)
    • Cohort 5 (n=6), HR- / HER2+ (pelareorep + trastuzumab + atezolizumab)

    The study combines pelareorep, without or with atezolizumab, and the standard of care therapy according to breast cancer subtype. Tumor tissue is collected from patients as part of their initial breast cancer diagnosis, again on day three following initial treatment, and finally at three weeks following treatment, on the day of their mastectomy. Data generated from this study are intended to confirm that pelareorep is acting as a novel immunotherapy, to evaluate potential synergy between pelareorep and checkpoint blockade, and to provide comprehensive biomarker data by breast cancer subtype. The primary endpoint of the study is overall CelTIL score (a measurement of cellularity and tumor-infiltrating lymphocytes). Secondary endpoints for the study include CelTIL by breast cancer subtype, safety, and tumor and blood-based biomarkers.

    For more information about the AWARE-1 study, refer to https://clinicaltrials.gov/ct2/show/NCT04102618.

    Tecentriq® (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.

    About BRACELET-1

    The BRACELET-1(BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti- PD-L1 and Paclitaxel) study is an open-label, phase 2, randomized study in patients with HR+/HER2-, endocrine-refractory metastatic breast cancer being conducted under a co-development agreement with Merck KGaA, Darmstadt, Germany and Pfizer. PrECOG LLC, a leading cancer research network, is managing the study. The study will take place at 20 trial sites and is expected to enroll 45 patients randomized into three cohorts. A three-patient safety run-in was conducted with patients receiving pelareorep, paclitaxel, and avelumab prior to randomization. The three cohorts being treated are as follows:

    • Cohort 1 (n=15): paclitaxel

    • Cohort 2 (n=15): paclitaxel + pelareorep

    • Cohort 3 (n=18): paclitaxel + pelareorep + avelumab (Bavencio®)

    Patients in cohort 1 will receive paclitaxel on days 1, 8, and 15 of a 28-day cycle. Patients in cohort 2 will receive the same paclitaxel regimen as cohort 1, plus pelareorep on days 1, 2, 8, 9, 15 and 16 of the 28-day cycle. Patients in cohort 3 will receive the same combination and dosing regimen as cohort 2, plus avelumab on days 3 and 17 of the 28-day cycle. The primary endpoint of the study is overall response rate. Exploratory endpoints include peripheral and tumor T cell clonality, inflammatory markers, and safety and tolerability assessments.

    For more information about the BRACELET-1 study, refer to https://clinicaltrials.gov/ct2/show/NCT04215146.

    About GOBLET

    The GOBLET (Gastrointestinal tumOrs exploring the treatment comBinations with the oncolytic reovirus peLarEorep and anTi-PD-L1) study is a phase 1/2 multiple indication biomarker, safety, and efficacy study in advanced or metastatic gastrointestinal tumors. The study will be conducted at 15 centers in Germany. The primary endpoint of the study is safety, with overall response rate and biomarker evaluation (T cell clonality and CEACAM6) as exploratory endpoints. Approximately 55 patients are planned to be enrolled in four independent cohorts:

    1. Pelareorep in combination with atezolizumab, gemcitabine, and nab-paclitaxel in 1st line metastatic pancreatic cancer patients (n=12);
    2. Pelareorep in combination with atezolizumab in 1st line MSI (microsatellite instability)-high metastatic colorectal cancer patients(n=19);
    3. Pelareorep in combination with atezolizumab and TAS-102 in 3rd line metastatic colorectal cancer patients (n=14); and
    4. Pelareorep in combination with atezolizumab in 2nd line advanced and unresectable anal cancer patients (n=10).

    About Oncolytics Biotech Inc.

    Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; our goals, objectives and strategies; our plans to further develop pelareorep through collaborations; our financial foundation; our anticipated catalysts and milestones; and other statements related to anticipated developments in Oncolytics' business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

    Company Contact

    Jon Patton

    Director of IR & Communication

    +1-858-886-7813

    jpatton@oncolytics.ca

    Investor Relations for Oncolytics

    Timothy McCarthy

    LifeSci Advisors

    +1-917-679-9282

    tim@lifesciadvisors.com 

     

    Cision View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-reports-2021-second-quarter-development-highlights-and-financial-results-301350059.html

    SOURCE Oncolytics Biotech® Inc.

    View Full Article Hide Full Article
  5. SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.

    Oncolytics

    Presenter: Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.
    Date: Thursday, August 12, 2021
    Time: 1:30 p.m. Eastern Daylight Time
    Webcast Link: Please click here

    The Company will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Canaccord Genuity representative or email jpatton@oncolytics.ca.

    A live webcast of the fireside chat will…

    SAN DIEGO and CALGARY, AB, Aug. 6, 2021 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC) today announced that the Company will participate in a fireside chat at the Canaccord Genuity 41st Annual Growth Conference, which is taking place virtually from August 10-12, 2021. Presentation details are listed below.

    Oncolytics

    Presenter: Dr. Matt Coffey, President & Chief Executive Officer of Oncolytics Biotech Inc.

    Date: Thursday, August 12, 2021

    Time: 1:30 p.m. Eastern Daylight Time

    Webcast Link: Please click here

    The Company will also be participating in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Canaccord Genuity representative or email jpatton@oncolytics.ca.

    A live webcast of the fireside chat will also be available on the Investor Relations page of Oncolytics' website (LINK) and will be archived for 90 days.

    About Oncolytics Biotech Inc.

    Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers.

    Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Oncolytics is currently conducting and planning clinical trials evaluating pelareorep in combination with checkpoint inhibitors and targeted therapies in solid and hematological malignancies as it advances towards a registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.

    This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking statements and forward-looking information are collectively referred to herein as "forward-looking statements"). Forward-looking statements contained in this press release include statements regarding Oncolytics' belief as to the potential and benefits of pelareorep as a cancer therapeutic; Oncolytics' expectations as to the purpose, design, outcomes and benefits of its current or pending clinical trials involving pelareorep; and other statements related to anticipated developments in Oncolytics' business and technologies.  In any forward-looking statement in which Oncolytics expresses an expectation or belief as to future results, such expectations or beliefs are expressed in good faith and are believed to have a reasonable basis, but there can be no assurance that the statement or expectation or belief will be achieved. Such forward-looking statements involve known and unknown risks and uncertainties, which could cause Oncolytics' actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely completion of clinical studies and trials, Oncolytics' ability to successfully commercialize pelareorep, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. In particular, we may be impacted by business interruptions resulting from COVID-19 coronavirus, including operating, manufacturing supply chain, clinical trial and project development delays and disruptions, labour shortages, travel and shipping disruption, and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how Oncolytics may be affected if the COVID-19 pandemic persists for an extended period of time. We may incur expenses or delays relating to such events outside of our control, which could have a material adverse impact on our business, operating results and financial condition.  Investors should consult Oncolytics' quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake any obligation to update these forward-looking statements, except as required by applicable laws.

    Company Contact

    Jon Patton

    Director of IR & Communication

    +1-858-886-7813

    jpatton@oncolytics.ca

    Investor Relations for Oncolytics

    Timothy McCarthy

    LifeSci Advisors

    +1-917-679-9282

    tim@lifesciadvisors.com

     

    Cision View original content:https://www.prnewswire.com/news-releases/oncolytics-biotech-to-participate-in-virtual-fireside-chat-at-the-canaccord-genuity-41st-annual-growth-conference-301349912.html

    SOURCE Oncolytics Biotech® Inc.

    View Full Article Hide Full Article
View All Oncolytics Biotech Inc. News